Synthesis and pharmacological analysis of a morphine/substance P chimeric molecule with full analgesic potency in morphine-tolerant rats

Medical Science Monitor

Volumn 13, Issue 2, 2007, Pages

  Kream, Richard M ^a,b,c   Liu, Nai Jiang ^a   Zhuang, Maojuan ^a   Esposito, Pamela L ^b   Esposito, Thomas R ^b   Stefano, George B ^b,c   Witmeyer III, John J ^b  

^a SUNY Downstate Medical Center   (United States)

^b Chimeracom LLC   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

Author keywords

Antinociception; Drug abuse; Hybrid chimeric molecules; Morphine; Opioid tolerance; Substance P

Indexed keywords

ANTINOCICEPTIVE AGENT; DELTA OPIATE RECEPTOR; KAPPA OPIATE RECEPTOR; MORPHINE; MSP 9; OPIATE ANTAGONIST; OPIATE RECEPTOR; SUBSTANCE P; SUBSTANCE P ANTAGONIST; SUBSTANCE P RECEPTOR; UNCLASSIFIED DRUG;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG POTENCY; DRUG SYNTHESIS; KINETICS; MALE; NONHUMAN; RAT; TAIL FLICK TEST;

ANIMALS; DRUG TOLERANCE; MALE; MORPHINE; MORPHINE DEPENDENCE; NARCOTICS; PAIN MEASUREMENT; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANCE P;

EID: 33846925112     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Go VL, Yaksh TL. Release of substance P from the cat spinal cord. J Physiol, 1987; 391: 141-67
2. Kar S, Quirion R. Neuropeptide receptors in developing and adult rat spinal cord: an in vitro quantitative autoradiography study of calcitonin gene-related peptide, neurokinins, mu-opioid, galanin, somatostatin, neurotensin and vasoactive intestinal polypeptide receptors. J Comp Neurol, 1995; 354: 253-81
3. Minami M, Maekawa K, Yabuuchi K, Satoh M: Double in situ hybridization study on coexistence of mu-, delta- and kappa-opioid receptor mRNAs with preprotachykinin A mRNA in the rat dorsal root ganglia. Brain Res Mol Brain Res, 1995; 30: 203-10
4. Lamotte C, Pert CB, Snyder SH: Opiate receptor binding in primate spinal cord: distribution and changes after dorsal root section. Brain Res, 1976; 112: 407-12
5. Duggan AW, Hendry IA, Morton CR et al: Cutaneous stimuli releasing immunoreactive substance P in the dorsal horn of the cat. Brain Res, 1988; 451: 261-73
6. Hokfelt T, Elde R, Johansson O et al: The distribution of enkephalin-immunoreactive cell bodies in the rat central nervous system. Neuroscience Letters, 1977; 5: 25-31
7. Kream RM, Kato T, Shimonaka H et al: Substance P markedly potentiates the antinociceptive effects of morphine sulfate administered at the spinal level. Proc Natl Acad Sci USA, 1993; 90: 3564-68
8. Foran SE, Carr DB, Lipkowski AW et al: A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic. Proc Natl Acad Sci USA, 2000; 97: 7621-26
9. Foran SE, Carr DB, Lipkowski AW et al: Inhibition of morphine tolerance development by a substance P-opioid peptide chimera. J Pharmacol Exp Ther, 2000; 295: 1142-48
10. Maszczynska I, Lipkowski AW, Carr DB, Kream RM: Dual functional interactions of substance P and opioids in nociceptive transmission. Analgesia, 1998; 3: 1-10
11. Egleton RD, Abbruscato TJ, Thomas SA, Davis TP: Transport of opioid peptides into the central nervous system. J Pharm Sci, 1998; 87: 1433-39
12. Borchardt RT: Optimizing oral absorption of peptides using prodrug strategies. J Control Release, 1999; 62: 231-38
13. Stain-Texier F, Boschi G, Sandouk P, Scherrmann JM: Elevated concentrations of morphine 6-beta-D-glucuronide in brain extracellular fluid despite low blood-brain barrier permeability. Br J Pharmacol, 1999; 128: 917-24
14. Goumon Y, Muller A, Glattard E et al: Identification of morphine-6-glucuronide in chromaffin cell secretory granules. J Biol Chem, 2006; 281: 8082-89
15. Akbarzadeh A, Mehraby M, Zarbakhsh M, Farzaneh H: Design and synthesis of a morphine-6-succinyl-bovine serum albumin hapten for vaccine development. Biotechnol Appl Biochem, 1999; 30(Pt2): 139-46
16. Bolton AE, Hunter WM: The labelling of proteins to high specific radio-activities by conjugation to a 125I-containing acylating agent. Biochem J, 1973; 133: 529-39
17. Mantyh PW, Gates T, Mantyh CR, Maggio JE: Autoradiographic localization and characterization of tachykinin receptor binding sites in the rat brain and peripheral tissues. J Neurosci, 1989; 9: 258-79
18. Lei SZ, Lipkowski AW, Wilcox GL: Opioid and neurokinin activities of substance P fragments and their analogs. Eur J Pharmacol, 1991; 193: 209-15
19. Liu NJ, Chakrabarti S, Gintzler AR: Chronic morphine-induced loss of the facilitative interaction between vasoactive intestinal polypeptide and delta-opioid: involvement of protein kinase C and phospholipase Cbetas. Brain Res, 2004; 1010: 1-9
20. Buerkle H, Yaksh TL: Pharmacological evidence for different alpha 2-adrenergic receptor sites mediating analgesia and sedation in the rat. Br J Anaesth, 1998; 81: 208-15
21. Sriwatanakul K, Weis OF, Alloza JL et al: Analysis of narcotic analgesic usage in the treatment of postoperative pain. JAMA, 1983; 250: 926-29
22. Reisine T, Pasternak GW: Opioid analgesics and antagonists. In: Hardman JG and Limbird LE, editors. The pharmacological basis of therapeutics. New York: McGraw Hill, 1996; 521-56
23. Zadina JE, Kastin AJ, Ge LJ, Hackler L: Mu, delta, and kappa opiate receptor binding of Tyr-MIF-1 and of Tyr-W-MIF-1, its active fragments, and two potent analogs. Life Sci, 1994; 55: L461-66
24. Cho HJ, Basbaum AI: Ultrastructural analysis of dynorphin B-immunoreactive cells and terminals in the superficial dorsal horn of the deafferented spinal cord of the rat. J Comp Neurol, 1989; 281: 193-205
25. De Biasi S, Rustioni A: Glutamate and substance P coexist in primary afferent terminals in the superficial laminae of spinal cord. Proc Natl Acad Sci USA, 1988; 85: 7820-24
26. Iadarola MJ, Tang J, Costa E, Yang HY: Analgesic activity and release of [MET5]enkephalin-Arg6-Gly7-Leu8 from rat spinal cord in vivo. Eur J Pharmacol, 1986; 121: 39-48
27. Glazer EJ, Basbaum AI: Opioid neurons and pain modulation: an ultrastructural analysis of enkephalin in cat superficial dorsal horn. Neuroscience, 1983; 10: 357-76
28. LaMotte CC, de Lanerolle NC: Ultrastructure of chemically defined neuron systems in the dorsal horn of the monkey. II. Methionine-enkephalin immunoreactivity. Brain Res, 1983; 274: 51-63
29. Ding YQ, Nomura S, Kaneko T, Mizuno N: Co-localization of mu-opioid receptor-like and substance P-like immunoreactivities in axon terminals within the superficial layers of the medullary and spinal dorsal horns of the rat. Neurosci Lett, 1995; 198: 45-48
30. Arvidsson U, Riedl M, Chakrabarti S et al: Distribution and targeting of a mu-opioid receptor (MOR1) in brain and spinal cord. J Neurosci, 1995; 15: 3328-41
31. Nakatsuka T, Chen M, Takeda D et al: Substance P-driven feed-forward inhibitory activity in the mammalian spinal cord. Mol Pain, 2005; 1: 20